These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15163493)

  • 1. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
    Hurt AC; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
    Bauer K; Richter M; Wutzler P; Schmidtke M
    Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rapid identification of human influenza neuraminidase N1 and N2 subtypes by ELISA.
    Barr IG; McCaig M; Durrant C; Shaw R
    Vaccine; 2006 Nov; 24(44-46):6675-8. PubMed ID: 16860447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
    Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
    Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
    Aoki FY; Hayden FG
    Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in pharmacology. New treatments for influenza: neuraminidase inhibitors.
    Cross J; Wedekind CA
    Med Health R I; 2001 Jun; 84(6):209-11. PubMed ID: 11434154
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
    Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.
    Tashiro M; McKimm-Breschkin JL; Saito T; Klimov A; Macken C; Zambon M; Hayden FG;
    Antivir Ther; 2009; 14(6):751-61. PubMed ID: 19812437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Critical review of anti-influenza drugs].
    van Loon FP; Voordouw AC; Simonian S; Koopmans PP
    Ned Tijdschr Geneeskd; 2000 Jan; 144(4):165-7. PubMed ID: 10668542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro.
    Baigent SJ; Bethell RC; McCauley JW
    Virology; 1999 Oct; 263(2):323-38. PubMed ID: 10544106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuraminidase inhibitor, anti-influenzal agent--mechanism of action, and how to use clinically].
    Kaji M
    Nihon Rinsho; 2003 Nov; 61(11):1975-9. PubMed ID: 14619441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
    Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
    Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiviral agents for influenza].
    Mitamura K
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():798-803. PubMed ID: 12722319
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
    Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
    J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.